Javelin’s Dyloject On Track For 1H 2009 NDA Filing; PMI-150 Needs Additional Efficacy Study
This article was originally published in The Pink Sheet Daily
Executive Summary
Following Dec. U.K. Dyloject launch, firm plans to market the NSAID in other European markets during the second half of next year.
You may also be interested in...
Abraxis Buys Shimoda; Dyloject Stays With Javelin
Upfront cash seems “ridiculously low,” analyst tells “The Pink Sheet” DAILY.
Abraxis Buys Shimoda; Dyloject Stays With Javelin
Upfront cash seems “ridiculously low,” analyst tells “The Pink Sheet” DAILY.
Javelin’s Intranasal Morphine Meets Phase III Primary Endpoint
Morphine delivered using Javelin’s proprietary technology could offer simpler, effective alternative to other postoperative opioids, firm says.